Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Genetics
Novelty and inventive step of patent owned by ERS Genomics and Emmanuelle Charpentier withstand challenge at Japan Patent Office | Invalidity proceedings also rejected by JPO in 2021.   14 December 2023
Big Pharma
Court rules that patent must be later-filed to be available as OTDP reference | MSN had submitted ANDA for generic version of Parkinson’s treatment Nuplazid.   14 December 2023
Big Pharma
US government takes on price gouging in latest raft of proposals | IP attorney says the “unfortunate decision” will deter future public-private collaboration | Move prompts concern over government's future use of march-in rights.   12 December 2023
Big Pharma
Hearing is latest in dispute between the biotech research firms | Multi-jurisdictional case concerns patents relating to the in-situ detection of analytes.   12 December 2023
Big Pharma
Case dismissed with settlement between Novartis and Daiichi Sankyo unit | Melanoma therapy at centre of feud after Novartis faced infringement claims over Tafinlar.   7 December 2023
Big Pharma
The UK pharmaceutical company filed three lawsuits against Sun Pharma | Sun’s abbreviated new drug application for generic versions of diabetes medications sparks fightback.   7 December 2023
Biotechnology
Emcure fends off COVID-19 trade secrets suit in Washington | A US biotech had inked a short-lived deal with Indian generic pharma company’s subsidiary.   5 December 2023
Big Pharma
USPTO director remanded case back to PTAB after it denied post-grant review of Spruce patents | Judges determined likelihood of claims being unpatentable due to prior art and lack of written description.   5 December 2023
Americas
Two new partners, who have been appointed at the Canadian law firm’s Toronto office, bring ‘extensive’ track records of success in complex patent litigation.   5 December 2023
Generics
Final award follows and incorporates the August 2022 decision by the arbitrator denying all claims levied at the Japanese company | Dispute involves antibody drug conjugate technology.   30 November 2023